Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Madison Dividend Income Fund John Brown, Drew Justman | “Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears. Our work suggests disruption fears are overexaggerat” | BULL | Q1 2026 Apr 18, 2026 | View Pitch |
Invesco Small Cap Value Fund Jonathan Edwards, Jonathan Mueller | “Charles River Laboratories was added as a new position. This leading CRO supports the discovery, development and safe manufacture of new drugs, biologics, vaccines and medical devices. It has a diversified portfolio with exposure to high growth therapeutic areas. Slower spending on biotech and pharma research and development has been a headwind to the stock, which gave us an opportunity to invest at what we saw as an attractive discount to our estimate of intrinsic value. BSD Analysis: Charles River Laboratories is positioned for a significant recovery in 2026 as biopharma R&D spending stabilizes following a post-pandemic correction. The company maintains a "Buy" consensus from the majority of analysts, with projections indicating a significant upside from its 52-week lows. For 2026, the investment case is bolstered by the firm's dominant position in the early-stage drug discovery and safety assessment market, which serves as a prerequisite for nearly all clinical trials. Management is successfully leveraging AI-powered data analytics to improve lead optimization and reduce drug development timelines for its clients. While operating margins faced some pressure during the previous cycle, the company's aggressive cost-management and capacity optimization are expected to drive margin expansion through 2026. The stock's current valuation is viewed as attractive by institutional investors, particularly as biotech funding begins to show a sustained rebound. For 2026, Charles River remains a core holding for those betting on the long-term industrialization of drug discovery.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Ariel Appreciation Fund John W. Rogers | “Charles River Laboratories (CRL) also traded higher on solid quarterly results, reinforcing its position as a leader in outsourced drug development services. While biotech funding and large pharma budgets have moderated, outsourcing demand remains resilient and we believe CRL's scale and capabilities position it well for recovery. Although near-term growth is pressured as big pharma prioritizes clinical programs over nonclinical work, we view these shifts as temporary since nonclinical testing is essential to replenishing pipelines. Longer term, CRL's diversified portfolio and investments in high-growth areas like cell and gene therapy support durable growth and margin expansion. The company is streamlining operations, divesting non-core assets and maintaining leverage below 3x, while a new $1B share repurchase authorization underscores confidence in its outlook. Despite macro uncertainty and near-term headwinds, we believe CRL's market opportunity is large, regulated and enduring; and its breadth and pricing power position it for renewed growth as demand normalizes. BSD Analysis: Charles River is a backbone supplier to drug discovery, embedded so deeply in R&D workflows that switching is often impractical. Biotech funding slowdowns hit volumes, but they don't eliminate demand — they delay it. The company benefits disproportionately when funding cycles turn back on. Its breadth across discovery, safety assessment, and manufacturing services creates cross-selling advantages. Margin pressure has exposed operating leverage in both directions. Investors treat current weakness as structural rather than cyclical. The installed base and regulatory complexity protect long-term relevance. As pipelines restart, utilization snaps back quickly. This is a picks-and-shovels name temporarily priced like broken equipment.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Madison Small Cap Fund Faraz Farzam, Aaron Garcia | “We initiated a position in Charles River Labs in Q3. CRL is a high-quality company in the drug discovery and development outsourcing space with a broad range of services from basic research to contract manufacturing. The company has operating margins of 20% or more and generates substantial free cash flow. The past few years have been challenging for companies in the drug development space, as capital has become increasingly constrained and research and development spending has remained stagnant. However, CRL has the operating history and mix of businesses to be successful over the long term. The customer base is diverse and CRL benefits from the increased dynamics of outsourcing by its biopharmaceutical clients. The company's top line has grown at a 12% compound annual rate over the last 10 years, even with the recent downturn. Management is solid, and we've known them for decades. We believe Charles River's earnings power can reach approximately $15 in 2028, assuming modest growth. We also use a sum of the parts at ~12x EBITDA (earnings before interest, taxes, depreciation, and amortization) to assess the attractiveness of CRL. This implies an intrinsic value of $228. Importantly, we think we are being conservative, as we don't build in a resumption of double-digit revenue growth in our valuation framework. However, we anticipate revenue growth of 4% from 2024 to 2028 and a modest margin recovery, aided by restructuring and cost-outs. BSD Analysis: Charles River still sits at the center of preclinical drug development, with scale and scientific breadth that smaller CROs can't touch. Biopharma funding softness has created noise, but backlog quality and specialty services remain strong. Regulatory overhangs have moderated, and margins are improving as capacity normalizes. Despite temporary headwinds, CRL remains a mission-critical partner in the pharma value chain. The stock is priced for stagnation; the business is anything but.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
